SOURCE: Corcept Therapeutics

Corcept Therapeutics

May 04, 2017 08:30 ET

Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress

MENLO PARK, CA--(Marketwired - May 4, 2017) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that presentations about hypercortisolism and mifepristone's role in treating that disorder will be presented at the 26th Annual Congress of the American Association of Clinical Endocrinologists (AACE) being held at the Austin Convention Center in Austin, Texas.

"There is growing awareness that even less severe degrees of hypercortisolism are harmful," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "As a result, physicians are increasingly screening patients whose metabolic and cardiovascular symptoms have not responded to conventional therapy and finding cases of previously undetected Cushing's syndrome." 

In addition to viewing the posters described below, AACE attendees may attend "Evolving Paradigms of Hypercortisolism," a product theater talk by Ty Carroll, M.D. Corcept is a sponsor of the talk.

Thursday, May 4, 2017
Poster #124
Screening of Diabetic Patients Using U500
Insulin Uncovers a High Percentage of Undiagnosed Hypercortisolism Consistent
with Cushing Syndrome
Joseph W. Mathews, M.D., FACE
James J. Smith, PhD
Friday, May 5, 2017, 12:45 - 1:30pm 
Product Theater B
Evolving Paradigms of Hypercortisolism Ty Carroll, M.D.
Friday, May 5, 2017
Poster #131
Medical Management of Mild Hypercortisolism and Primary Aldosteronism in a Patient with
ACTH-Independent Macronodular Hyperplasia
Presenting with Resistant Hypertension
Sandi-Jo Galati, M.D.
Michele Lamerson, RN, MS, CPNP
Poster #608
Improving Glycemic Control with Mifepristone
in Cushing Syndrome Patients May Lead
to Significant Weight-loss
Adriana G. Ioachimescu, M.D., PhD, FACE
Jonathan G. Ownby, M.D., FACE
Nicole G. Greyshock, M.D., FACE
Thomas C. Jones, M.D., FACE
Gary S. Wand, M.D., PhD, FACE
James J. Smith, PhD
Poster #725
Successful Medical Management with Mifepristone in a Patient with Occult Ectopic Cushing Syndrome
Saima Farghani, M.D.
Michele Lamerson, RN, MS, CPNP
Poster #836
Mifepristone Therapy Significantly Improved
Insulin Resistance, Glycemic Control, and Weight Loss in a Patient with Cushing Disease
Previously Treated with Pasireotide
Jonathan G. Ownby, M.D., FACE
James J. Smith, PhD
Poster #839
Mifepristone Reduced U500 Insulin Usage in a Patient with Cushing Disease and Normalized Concomitant Fatty Liver Disease and Retinopathy
Kimberley A. Bourne, M.D., FACE
James J. Smith, PhD

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.

Contact Information